Friday, March 14, 2025
3/14/2025
PROJECT ABSTRACT There is a massive prevalence of diabetes in the U.S. with 34.2 million having diabetes, and 88 million adults with prediabetes. Type 1 diabetes results from the autoimmune destruction of the islet β cell mediated in part by β-cell dysfunction prior to autoimmune attack. Polyamine and hypusine production are important for the translation of a subset of RNAs involved in the unfolded protein response, ER stress, and cytokine response in the β cell. Our preliminary data suggests that the polyamine/hypusine pathway is involved in the translation of proteins required for the response of the β cell to inflammation. Inhibition of two rate limiting enzymes along the polyamine/hypusine pathway, either genetically or with small molecule inhibitors, results in a decrease of ER stress leading to protection from β-cell death and ultimately type 1 diabetes. For this proposal we will use a combination of mouse, and human models to understand how the polyamines and hypusine specifically alter the β cell’s response to stress. We propose to study the role of polyamines and hypusine in specific mRNA translation of proteins that are important to the maladaptive response of β-cell ER stress and hypothesis that polyamine depletion leads to ER stress resolution, preserved β-cell function, and ultimately reduced T1D pathogenesis. To test this hypothesis, we propose the following aims: Aim 1: Interrogate the molecular mechanisms by which the polyamine/hypusine pathway contributes to β-cell dysfunction and death. Aim 2: Determine the role of β cell polyamine/hypusine pathway during autoimmunity and the development of T1D. Aim 3: Assess the efficacy of treatment with polyamine/hypusine blockade. The primary impact of this proposal is the identification of mechanisms of the polyamine/hypusine pathway in β cells during the diabetes pathogenesis.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).